Abstract
Ophthalmic liposomes of ganciclovir (GCV) were prepared by the reverse phase evaporation method, and their ocular pharmacokinetics in albino rabbits were compared with those obtained after dosing with GCV solution. The in vitro transcorneal permeability of GCV liposomes was found to be 3.9-fold higher than that of the solution. After in vivo instillation in albino rabbits, no difference was found in the precorneal elimination rate of GCV from liposome vs solution dosing. The aqueous humor concentration-time profiles of both liposomes and solution were well described by 2-compartmental pharmacokinetics with first-order absorption. The area under the curve of the aqueous humor concentration-time profiles of GCV liposomes was found to be 1.7-fold higher than that of GCV solution. Ocular tissue distribution of GCV from liposomes was 2 to 10 times higher in the sclera, cornea, iris, lens, and vitreous humor when compared with those observed after solution dosing. These results suggested that liposomes may hold some promise in ocular GCV delivery.
Keywords: Ganciclovir, liposomes, precorneal clearance, ocular pharmacokinetics
Full Text
The Full Text of this article is available as a PDF (504.3 KB).
References
- 1.Mar E, Cheng Y, Huang Y. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983;24:518–521. doi: 10.1128/aac.24.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Martin J, Dvorack C, Smee D, Matthews T, Verheyden J. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J Med Chem. 1983;26:759–761. doi: 10.1021/jm00359a023. [DOI] [PubMed] [Google Scholar]
- 3.Cantrill H, Henry K, Melroe N, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology. 1989;96:367–374. doi: 10.1016/s0161-6420(89)32900-9. [DOI] [PubMed] [Google Scholar]
- 4.Markham A, Faulde D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs. 1994;48:455–460. doi: 10.2165/00003495-199448030-00009. [DOI] [PubMed] [Google Scholar]
- 5.Maudgal P, Clercq K, Descamps J, Missotten L. Topical treatment of experimental herpes simplex keratouveitis with 2′-O-glycylacyclovir, a water-soluble ester of acyclovir. Arch Opthalmol. 1984;102:140–142. doi: 10.1001/archopht.1984.01040030118049. [DOI] [PubMed] [Google Scholar]
- 6.Hughes P, Mitra A. Effect of acylation on the ocular disposition of acyclovir. II. Corneal permeability and anti-HSV 1 activity of 29-esters in rabbit epithelial keratitis. J Ocul Pharmacol. 1993;9:299–309. doi: 10.1089/jop.1993.9.299. [DOI] [PubMed] [Google Scholar]
- 7.Drew W. Is combination antiviral therapy for CMV superior to monotherapy? J Clin Virol. 2006;35:485–488. doi: 10.1016/j.jcv.2005.09.021. [DOI] [PubMed] [Google Scholar]
- 8.Wiltink E, Stekkinger P, Brakenhoff J, Danner S. Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reverse-phase high pressure liquid chromatography. Pharm Weekbl Sci. 1987;9:261–264. doi: 10.1007/BF01953628. [DOI] [PubMed] [Google Scholar]
- 9.Choonara Y, Pillay V, Carmichael T, et al. An in vitro study of the design and development of a novel doughnut-shaped minitablet for intraocular implantation. Int J Pharm. 2006;310:15–24. doi: 10.1016/j.ijpharm.2005.10.019. [DOI] [PubMed] [Google Scholar]
- 10.Law S, Huang K, Chiang C. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63:135–140. doi: 10.1016/S0168-3659(99)00192-3. [DOI] [PubMed] [Google Scholar]
- 11.Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1966. [Google Scholar]
- 12.Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA. 1978;75:4194–4198. doi: 10.1073/pnas.75.9.4194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Wu P. The characterization and biodistribution of cefoxitin-loaded liposomes. Int J Pharm. 2004;271:31–39. doi: 10.1016/j.ijpharm.2003.10.034. [DOI] [PubMed] [Google Scholar]
- 14.Law S, Hung H. Properties of acyclovir-containing liposomes for potential ocular delivery. Int J Pharm. 1998;161:253–259. doi: 10.1016/S0378-5173(97)00362-1. [DOI] [Google Scholar]
- 15.Durrani A, Farr S, Kellaway I. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharm. 1995;118:243–250. doi: 10.1016/0378-5173(94)00389-M. [DOI] [Google Scholar]
- 16.McSharry J, McDonough A, Olson B, et al. Inhibition of ganciclovir-susceptible and-resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol. 2001;8:1279–1281. doi: 10.1128/CDLI.8.6.1279-1281.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.McCalden T, Levy M. Retention of topical liposomal formulation on the cornea. Experientia. 1990;46:713–715. doi: 10.1007/BF01939943. [DOI] [PubMed] [Google Scholar]
- 18.Pleyer U, Lutz S, Jusko W, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci. 1993;34:2737–2742. [PubMed] [Google Scholar]
- 19.Elsayed M, Abdallah O, Naggar V, et al. Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm. 2006;322:60–66. doi: 10.1016/j.ijpharm.2006.05.027. [DOI] [PubMed] [Google Scholar]